Allovir Stock News

AlloVir press release (ALVR): FY GAAP EPS of -$2.74 misses by $0.10.As of December 31, 2021, company had cash, cash equivalents and marketable securities of $248.1 million, compared…

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today reported full-year 2021 financial results for the period ended December 31, 2021. The company also provided the outlook for 2022 across its pipeline of allogeneic, off-the-shelf, virus-specific T cell (VST) therapies for immunocompromised patients, including its lead product posoleucel, an investigational VST in development for the treatment and prevention of infections

AlloVir manufactures T cells ex vivo, off-the-shelf, for curing viral infections in HSCT patients. Click here for a review of ALVR''s manufacturing process.

AlloVir: A Comparative Study Of Its Manufacturing Process

AlloVir Inc (ALVR) shares closed today at 1.3% above its 52 week low of $10.10, giving the company a market cap of $666M. The stock is currently down 20.9% year-to-date, down 75.7% over the past 12 months, and down 59.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 34.4% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 669.0% The company's stock price performance over the past 12 months lags the peer average by 149.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

AlloVir (NASDAQ:ALVR) had its price objective lowered by equities research analysts at SVB Leerink from $37.00 to $32.00 in a research note issued to investors on Friday, Price Targets.com reports. The brokerage currently has an outperform rating on the stock. SVB Leerinks price objective points to a potential upside of 125.04% from the stocks previous []

AlloVir (NASDAQ:ALVR) had its target price decreased by SVB Leerink from $37.00 to $32.00 in a research note published on Friday, Price Targets.com reports. SVB Leerink currently has an outperform rating on the stock. Other equities research analysts have also recently issued research reports about the company. Morgan Stanley upped their price target on AlloVir []

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck Announces Publication Of Positive Data From Late-Stage Study Of Oral COVID-19 Antiviral Treatmen

WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced preliminary data from the ongoing open-label portion of a Phase 2 study assessing the safety and efficacy of posoleucel (Viralym-M, ALVR105) for the prevention of clinically significant infections and end-organ diseases from six potentially life-threatening viruses in high-risk patients following allogeneic hematopoietic cell transplantation (allo-HCT). Out of

AlloVir, Inc. (NASDAQ:ALVR) Stock analysts at Piper Sandler cut their FY2025 earnings per share (EPS) estimates for shares of AlloVir in a research report issued to clients and investors on Monday, December 6th. Piper Sandler analyst C. Raymond now forecasts that the company will post earnings per share of ($3.30) for the year, down [] The post Brokers Issue Forecasts for AlloVir, Inc.s FY2025 Earnings (NASDAQ:ALVR) appeared first on ETF Daily News .

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r

UBS Asset Management Americas Inc. bought a new position in shares of AlloVir, Inc. (NASDAQ:ALVR) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 13,356 shares of the companys stock, valued at approximately $264,000. A number of other institutional investors []

iTeos Therapeutics (NASDAQ:ITOS) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability. Earnings & Valuation This table compares iTeos Therapeutics and AlloVirs revenue, earnings per share and valuation. []

California State Teachers Retirement System trimmed its holdings in shares of AlloVir, Inc. (NASDAQ:ALVR) by 8.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,671 shares of the companys stock after selling 3,981 shares during the period. California []